May 27, 2026

Designed to deliver clear vision1 and high levels of comfort2,3 for presbyopic patients, alongside a proven, easy fitting experience for optometrists.4

SYDNEY, 27 May 2026 – CooperVision today announced the launch of clariti® 1 day multifocal with CooperVision Binocular Progressive System®1 in Australia and New Zealand, available from 1 June 2026. The new upgraded lens features several next-generation enhancements designed to provide better vision1 and high levels of comfort2,3 for presbyopic patients, along with an easy and successful fitting experience4 for optometrists.

Nearly two billion people worldwide now experience presbyopia5, yet multifocal contact lenses remain significantly underutilised, representing a major missed opportunity for both patients and eye care professionals6.

The clariti® 1 day multifocal builds on CooperVision’s long-standing leadership in soft contact lenses*7, offering the widest range of prescription options across spherical, toric and multifocal lenses†8. Supported by proven Binocular Progressive System® technology already trusted in MyDay® multifocal9, CooperVision continues to set the benchmark in presbyopia management worldwide.

“The launch of clariti® 1 day multifocal with Binocular Progressive System® represents a significant step forward for our clariti® 1 day portfolio, with the upgrade reflecting our commitment to innovation across our silicone hydrogel one-day product families,” said Michelle North, General Manager CooperVision Australia and New Zealand. “By applying the same advanced lens design introduced in our highly regarded MyDay® multifocal,9 we’re giving optometrists in Australia and New Zealand an excellent product to address the growing needs of presbyopic patients.”

The clariti® 1 day multifocal with CooperVision Binocular Progressive System® maintains the features optometrists and wearers value about the lens,10,11,12 while providing improved visual acuity at all distances.1 Key enhancements include:

  • CooperVision Binocular Progressive System® – the innovative technology originally developed for the widely adopted MyDay® multifocal9 provides a streamlined fitting process that makes it easier for practitioners to fit patients with the right lens from the start11 with the widest power range of any 1-day multifocal.13
  • Optimised Comfort Edge™ – helping to provide good comfort.14
  • WetLoc® Technology – helping to maintain lens hydration throughout the day.15

Simplified fitting, high fit success rates

Historically, multifocal contact lenses have been perceived as complex and time-consuming to fit — limiting adoption despite strong patient demand16. CooperVision’s Binocular Progressive System®1 directly addresses these barriers, delivering a streamlined, evidence-backed fitting approach that has achieved fitting success in 98% of patients with two pairs of lenses or fewer.17

“For optometrists, the combination of a simplified fitting process and strong fitting success data makes a real difference in practice,” said Joe Tanner, Head of Professional Affairs, CooperVision ANZ. “Presbyopic patients often present with a variety of visual needs, and the clariti® 1 day multifocal allows practitioners to deliver better vision1 and comfort2,3 using an efficient fitting approach.”4

Optometrist and Melbourne-based practice owner, Genevieve Hastings said “From my experience in practice, presbyopia represents one of the biggest growth opportunities in contact lenses. With continuing advances in multifocal contact lens technology – better optics and a broader, more sophisticated range available – we can offer patients both excellent vision and lifestyle benefits. That said, these innovative lenses remain underutilised and there’s a genuine opportunity to do more for this group of patients.”

The complete clariti® 1 day portfolio

The full family of clariti® 1 day lenses – sphere, toric, and multifocal – offers all-day comfort15 and features easy handling18 and high oxygen transmissibility‡19, 20, 21 which allows for 100% corneal oxygen consumption to help maintain ocular health during daily wear.

For more information, visit www.coopervision.net.au or www.coopervision.net.nz

# # #

About CooperVision

CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of one-day, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges, such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas, and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

About CooperCompanies

CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, California, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding a product launch and features and technologies that may impact demand for new products. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause actual results and future actions to differ materially from those described in forward-looking statements are risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new or alternative products; potential product performance, availability and quality issues; competition; launch delays; and other factors described in CooperCompanies’ Securities and Exchange Commission filings, including the “Business”, “Risk Factors” and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in Cooper’s Annual Report on Form 10-K for the fiscal year ended October 31, 2024, as such Risk Factors may be updated in annual and quarterly filings. CooperCompanies cautions investors that forward-looking statements reflect the company’s analysis only on their stated date. CooperCompanies disclaims any intent to update them except as required by law.

Media Contact

Jacqui May

Email: hello@au.coopervision.com

Footnotes

* Combination of 2021 market research based on global volume data and internal estimates

† Based on Rx option combinations (sphere, cylinder, axis & add) manufactured, across all soft lenses in sphere, toric & multifocal (including made to order), in SiHy and hydrogel from 4 main manufacturers. Includes 1 Day, 2 weekly, and monthly disposable contact lenses. Cosmetic & Photochromatic contact lenses not included. Multiple base curve variants not included.

‡ Based on manufacturers published data (up to 3X sphere and multifocal and up to 2X toric).

§ When using the fitting guide or OptiExpert™. Fit success 98% MyDay® multifocal and 100% clariti® 1 day multifocal with two pairs or fewer.

References

  1. CVI data on file, 2024.
  2. CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 Add with a rating of 88 out of 100; n=90 habitual MFCL wearers.
  3. CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 Add; with a rating of 93 out of 100; n=90 habitual MFCL wearers.
  4. CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 Add; n=90.
  5. Fricke TR, Tahhan N, Resnikoff S, et al. Global Prevalence of Presbyopia and Vision Impairment from Uncorrected Presbyopia: A Systematic Review, Meta-analysis, and Modelling Ophthalmology. 2018;125(10):1432–1449. DOI: 10.1016/j.ophtha.2018.04.013
  6. CooperVision data on file. Global Multifocal Research, 2021.
  7. CVI data on file, 2022.
  8. CVI data on file, 2023. Industry reports and internal estimates based on Tyler’s Quarterly, 12/2022.
  9. CVI data on file, 2024. CVI data on file, 2022. Prospective, crossover, bilateral, subject masked, daily wear, dispensing study (4 clinical sites in U.S.) (n=58 habitual soft MFCL wearers).
  10. CVI data on file, 2019. Prospective, bilateral, subject-masked dispensing study with clariti® 1 day multifocal. N=48 habitual soft MFCL wearers at 2 sites in North America. *At baseline approximately 5 mins after lens insertion.
  11. CooperVision data on file, 2019. clariti® 1 day Wearer Experience Survey conducted online in U.S., n=298: sphere, toric or multifocal; habitual FRP, DD, and new wearers who purchased clariti® 1 day; strongly or somewhat agree.
  12. Orsborn G, Dumbleton K. Eye Care Professionals' Perceptions of the Benefits of Daily Disposable Silicone Hydrogel Contact Lenses, Contact Lens and Anterior Eye; 42 (2019) 4:373–379. CVI data on file, 2018. Survey results of ECPs in US, UK and Japan, n=300.
  13. CVI data on file 2024. Based on prescription option combinations (sph and add) available across all daily disposable multifocal soft lenses from CVI, JJV, B+L and Alcon in USA Feb 2024.
  14. CVI data on file, 2024. CVI data on file, 2022. Prospective, crossover, bilateral, subject masked, daily wear, dispensing study (4 clinical sites in U.S.) (n=58 habitual soft MFCL wearers)
  15. CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 Add; n=90 habitual MFCL wearers.
  16. CooperVision data on file, 2020. Kubic Online Survey of Eye Care Professionals (US, UK, Japan); n=477.
  17. CVI data on file, 2026.
  18. CVI data on file 2022. Verve Online Brand Survey with ECPs who recommend somofilcon A for new wearers in US, Spain, Italy, UK and Korea. n=249 (89% strongly agree/agree).
  19. Brennan NA. Beyond Flux: Total Corneal Oxygen Consumption as an Index of Corneal Oxygenation During Contact Lens Wear. Optom Vis Sci. 2005;82(6):467-472.
  20. Sulley A, Dumbleton K. Silicone hydrogel daily disposable benefits: The evidence. CLAE. 2020 Jun;43(3):298-307.
  21. Lumb E. & Symons A. Comparison of Dk/t values of daily disposable soft toric contact lenses using high resolution thickness profiling. BCLA Poster presentation at NCC 2016.

SA18744   MAY 2026

More News Articles